时珍国医国药2025，Vol.36Issue(6)：1014-1022,9.DOI:10.70976/j.1008-0805.SZGYGY-2025-0603
左归降糖清肝方含药血清调控线粒体功能改善HepG2细胞脂肪性变的机制研究
Study on the mechanism of serum containing Zuogui Jiangtang Qinggan Formula(左归降糖清肝方)in regulating mitochondrial function to ameliorate steatosis in HepG2 cells
摘要
Abstract
Objective To investigate the mechanism by which the medicated serum of Zuogui Jiangtang Qinggan Formula(左归降糖清肝方,ZGJTQGF)regulates peroxisome proliferator-activated receptor-γ coactivator-1α(PGC-1α)-mediated mitochondrial function to ameliorate hepatic steatosis in HepG2 cells.Methods A cellular model of hepatic steatosis was established using oleic acid(OA)-induced HepG2 cells,followed by intervention with serum containing ZGJTQGF.Lipid accumulation was detected via Oil Red O staining.Intracellular triglyceride(TG),reactive oxygen species(ROS),ATP levels,and mitochondrial membrane potential(MMP)were measured using the assay kits.RT-PCR and Western blot(WB)were used to evaluate mRNA and protein expression of PGC-1α and its related genes.Results Compared with the control group,the model group showed significantly increased TG and ROS levels(P<0.01),decreased ATP content and MMP(P<0.01),down-regulated mRNA expressions of PGC-1α,NRF1,TFAM,and down-stream lipid metabolism-related genes(PPARα,ACOX1,CPT1α)(P<0.05),and up-regulated mRNA expression of the lipogenic gene FAS(P<0.05).Compared with the model group,all dose groups with medicated serum of ZGJTQGF ameliorated intracellular lip-id deposition,significantly reduced TG and ROS levels(P<0.01),increased ATP content and MMP(P<0.01),up-regulated mR-NA expressions of PGC-1α,NRF1,TFAM,PPARα,ACOX1,and CPT1α(P<0.05),and down-regulated FAS mRNA expression(P<0.05).The protective effects of ZGJTQGF were diminished by a PGC-1α inhibitor(P<0.05).Conclusion The medicated ser-um of ZGJTQGF ameliorates hepatic steatosis by regulating the PGC-1α expression,affecting mitochondrial biogenesis and lipid metabo-lism while improving mitochondrial function.关键词
非酒精性脂肪肝/左归降糖清肝方/HepG2细胞/PGC-1α/线粒体功能Key words
Nonalcoholic fatty liver disease/Zuogui Jiangtang Qinggan Formula(左归降糖清肝方)/HepG2 cells/PGC-1 α/Mitochondrial function分类
医药卫生引用本文复制引用
李亚楠,冯馨瑶,徐睿怡,李振祥,马桂秀,李萍,成细华..左归降糖清肝方含药血清调控线粒体功能改善HepG2细胞脂肪性变的机制研究[J].时珍国医国药,2025,36(6):1014-1022,9.基金项目
国家自然科学区域联合基金(U21A20411) （U21A20411）
湖南省卫生健康委员会重点项目(A202303066904) （A202303066904）
湖南省自然科学基金(2025JJ90275 （）
2025JJ90309) （）
湖南中医药大学研究生创新课题(2023CX159) （2023CX159）
湖南中医药大学本科生科研创新基金(2023BKS068,2024BKS093) （2023BKS068,2024BKS093）
湖南中医药大学一流学科基础医学资助项目 （）
湖南省国内一流培育学科中西医结合学科(2024) （2024）
血管生物学与转化医学湖南省重点实验室(2024) （2024）
中西医结合病原生物学湖南省重点实验室(2024) （2024）
